Pharmaceutical

Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities

Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gibson SOLA platform at R&D facilities.

May 30, 2025 - 06:00
Regeneron to deploy Telesis Bio’s Gibson SOLA at R&D facilities
Telesis Bio has announced a licensing agreement with Regeneron, enabling the latter to deploy the Gibson SOLA platform at R&D facilities.
Read the original article

Tags:

Previous Article

Solid tumours: CAR-T therapies’ Waterloo

Next Article

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

CTX-310 by CRISPR Therapeutics for Heterozygous familia...

Jul 6, 2024

Rosemont expands liquid medicine portfolio with Lucis acquisition

Rosemont expands liquid medicine portfolio with Lucis a...

Jun 19, 2023

U.S. health officials lay out plans to cope with respiratory virus season

U.S. health officials lay out plans to cope with respir...

Aug 25, 2023